Is a low dose of hepatitis B vaccine enough for a rapid vaccination scheme?

World Journal of Gastroenterology

Volumn 9, Issue 10, 2003, Pages 2353-2355

  Wang, Ru Xiang ^a   Boland, Greet ^b   Guo, Ying ^a   Lei, Shao Ping ^c   Yang, Chang Hong ^d   Chen, Juan ^a   Tian, Jie ^e   Wen, Jin Ying ^f   Du, Ke Hong ^g   Van Hattum, Jan ^b   De Gast, Gijsbert C ^h  

^a Shenyang Center for Disease Control and Prevention   (China)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Hosp Inst Shenyang Electri Power   (China)

^d Dongling Dist Anti Epidemic Station   (China)

^e Fourth People's Hospital of Shenyang   (China)

^f Shenyang 606 Hospital   (China)

^g Shenzhen Weiguang Biological Products Co Ltd   (China)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; NONHUMAN; SCHOOL CHILD; SEROCONVERSION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VACCINATION;

EID: 0142151226     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i10.2353     Document Type: Article

References (31)

1. Kojouharova M, Teoharov P, Bahtchevanova T, Maeva I, Eginlian A, Deneva M. Safety and immunogenicity of a yeast-derived recombinant hepatitis B vaccine in Bulgarian newborns. Infection 2001; 29: 342-344
2. Liao SS, Li RC, Li H, Yang JY, Zeng XJ, Gong J, Wang SS, Li JP, Zhang KL. Long-term efficacy of plasma-derived hepatitis B vaccine among Chinese children: A 12-year follow-up study. World J Gastroenterol 1999; 5: 165-166
3. Li H, Li RC, Liao SS, Yang JY, Zeng XJ, Wang SS. Persistence of hepatitis B vaccine immune protection and response to hepatitis B booster immunization. World J Gastroenterol 1998; 4: 493-496
4. Rendi-Wagner P, Kundi M, Stemberger H, Wiedermann G, Holzmann H, Hofer M, Wiesinger K, Kollaritsch H. Antibody-response to three recombinant hepatitis B vaccines: Comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001; 19: 2055-2060
5. Ozaki T, Mochizuki H, Ichikawa Y, Fukuzawa Y, Yoshida S, Morimoto M. Persistence of hepatitis B surface antibody levels after vaccination with a recombinant hepatitis B vaccine: A 3-year follow-up study. J Oral Sci 2000; 42: 147-150
6. Jain A, Mathur US, Jandwani P, Gupta RK, Kumar V, Kar P. A multicentric evaluation of recombinant DNA hepatitis B vaccine of Cuban origin. Trop Gastroenterol 2000; 21: 14-17
7. Al-Faleh FZ, Al-Jeffri M, Ramia S, Al-Rashed R, Arif M, Rezeig M, Al-Toraif I, Bakhsh M, Mishkkhas A, Makki O, Al-Freihi H, Mirdad S, AlJuma A, Yasin T, Al-Swailem A, Ayoola A. Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. J Infect 1999; 38: 167-170
8. Li H, Li RC, Liao SS, Gong J, Zeng XJ, Li YP. Long-term effectiveness of infant low dose hepatitis B vaccine immunization in Zhuang Minority Area in China. World J Gastroenterol 1999; 5: 122-124
9. Liu HB, Meng ZD, Ma JC, Han CQ, Zhang YL, Xing ZC, Zhang YW, Liu YZ, Cao HL. A 12 year cohort study on the efficacy of plasma-derived hepatitis B vaccine in rural newborns. World J Gastroenterol 2000; 6: 381-383
10. Li H, Wang L, Wang SS, Gong J, Zeng XJ, Li RC, Nong Y, Huang YK, Chen XR, Huang ZN. Research on optimal immunization strategies for hepatitis B in different endemic areas in China. World J Gastroenterol 2000; 6: 392-394
11. Zeng XJ, Yang GH, Liao SS, Chen AP, Tan J, Huang ZJ, Li H. Survey of coverage, strategy and cost of hepatitis B vaccination in rural and urban areas of China. World J Gastroenterol 1999; 5: 320-323
12. Shokri F, Jafarzadeh A. High seroprotection rate induced by low doses of a recombinant hepatitis B vaccine in healthy Iranian neonates. Vaccine 2001; 19: 4544-4548
13. Carlsson T, Struve J, Sonnerborg A, Weiland O. The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination. Scand J Infect Dis 1999; 31: 93-95
14. Young MD, Rosenthal MH, Dickson B, Du W, Maddrey WC. A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine. Vaccine 2001; 19: 3437-3443
15. Leroux-Roels G, Abraham B, FourneauM, De Clercq N, Safary A. A comparison of two commercial recombinant vaccines for hepatitis B in adolescents. Vaccine 2000; 19: 937-942
16. Treadwell TL, Keeffe EB, Lake J, Read A, Friedman LS, Goldman IS, Howell CD, DeMedina M, Schiff ER, Jensen DM. Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am J Med 1993; 95: 584-588
17. De Rave S, Heijtink RA, Bakker-Bendik M, Boot J, Schalm SW. Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers. Vaccine 1994; 12: 532-534
18. Bennett RG, Powers DC, Remsburg RE, Scheve A, Clements ML. Hepatitis B virus vaccination for older adults. J Am Geriatr Soc 1996; 44: 699-703
19. Yucesoy B, Sleijffers A, Kashon M, Garssen J, De Gruijl FR, Boland GJ, Van Hattum J, Simeonova PP, Luster MI, Van Loveren H. IL-1beta gene polymorphisms influence hepatitis B vaccination. Vaccine 2002; 20: 3193-3196
20. Jabaaij L, Van Hattum J, Vingerhoets JJ, Oostveen FG, Duivenvoorden HJ, Ballieux RE. Modulation of immune response to rDNA hepatitis B vaccination by psychological stress. J Psychosom Res 1996; 41: 129-137
21. Sleijffers A, Yucesoy B, Kashon M, Garssen J, De Gruijl FR, Boland GJ, Van Hattum J, Luster MI, Van Loveren H. Cytokine polymorphisms play a role in susceptibility to ultraviolet B-induced modulation of immune responses after hepatitis B vaccination. J Immunol 2003; 170: 3423-3428
22. Goldwater PN. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 1997; 15: 353-356
23. Wismans P, Van Hattum J, Stelling T, Poel J, De Gast GC. Effect of supplementary vaccination in healthy non-responders to Hepatitis B vaccination. Hepatogastroenterol 1988; 35: 78-79
24. Wismans P, Van Hattum J, Mudde GC, Endeman HJ, Poel J, De Gast GC. Is booster injection with hepatitis B vaccine necessary in healthy responders? J Hepatol 1988; 8: 236-240
25. Zaruba K, Grob PJ, Bolla K. Thymopentin as adjuvant therapy to hepatitis B vaccination in formerly non-or hyporesponding hemodialysis patients. Surv Immunol Res 1985; 4: S102-S106
26. Maruyama N, Sata M, Ishii K, Atono Y, Ono K, Matuda T, Suzuki H, Muraoka H, Nakano H, Hino K. Hepatitis B vaccination in alcoholics. Kansenshogaku Zasshi 1989; 63: 27-34
27. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: A prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12: 1204-1211
28. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines and vaccine protocol recommendations. Am J Med 1989; 87: 3A-36S
29. Erensoy S, Bilgic A, Arda B, Ozer O. Low-dose intramuscular hepatitis B vaccination in medical students: 4-year follow-up. Infection 2002; 30: 303-305
30. Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 1999; 29: 954-959
31. Clemens R, Sanger R, Kruppenbacher J, Hobel W, Stanbury W, Bock HL, Jilg W. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule-results of a post-marketing surveillance. Vaccine 1997; 15: 349-352